These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1282167)

  • 21. [Therapeutic application of myocardial cytoprotection].
    Ribeiro C
    Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of glibenclamide and nicorandil on cardiac function during ischemia and reperfusion in isolated perfused rat hearts.
    Mitani A; Kinoshita K; Fukamachi K; Sakamoto M; Kurisu K; Tsuruhara Y; Fukumura F; Nakashima A; Tokunaga K
    Am J Physiol; 1991 Dec; 261(6 Pt 2):H1864-71. PubMed ID: 1836311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is potassium channel opening an effective form of preconditioning before cardioplegia?
    Menasché P; Mouas C; Grousset C
    Ann Thorac Surg; 1996 Jun; 61(6):1764-8. PubMed ID: 8651781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects.
    Markham A; Plosker GL; Goa KL
    Drugs; 2000 Oct; 60(4):955-74. PubMed ID: 11085202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potassium channel openers in myocardial ischaemia: therapeutic potential of nicorandil.
    Gomma AH; Purcell HJ; Fox KM
    Drugs; 2001; 61(12):1705-10. PubMed ID: 11693460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nicorandil, a potent adenosine triphosphate-sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury.
    Yamashita M; Schmid RA; Fujino S; Cooper JD; Patterson GA
    J Thorac Cardiovasc Surg; 1996 Nov; 112(5):1307-14. PubMed ID: 8911328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Potassium agonists].
    Hellwig B
    Med Monatsschr Pharm; 1994 Jun; 17(6):164-7. PubMed ID: 8052166
    [No Abstract]   [Full Text] [Related]  

  • 28. Pretreatment with the adenosine triphosphate-sensitive potassium channel opener nicorandil and improved myocardial protection during high-potassium cardioplegic hypoxia.
    Sugimoto S; Puddu PE; Monti F; Schiariti M; Campa PP; Marino B
    J Thorac Cardiovasc Surg; 1994 Sep; 108(3):455-66. PubMed ID: 8078338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicorandil for angina.
    Drug Ther Bull; 1995 Dec; 33(12):89-92. PubMed ID: 8777891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Potential role of ATP-sensitive K+ channels in ischemia- and reperfusion-induced arrhythmias].
    Nakaya H
    Kokyu To Junkan; 1993 Jun; 41(6):512-20. PubMed ID: 8337509
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of an angiotensin-converting enzyme inhibitor and a K+(ATP) channel opener on warm up angina.
    Edwards RJ; Redwood SR; Lambiase PD; Marber MS
    Eur Heart J; 2005 Mar; 26(6):598-606. PubMed ID: 15618027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperpolarized cardioplegic arrest with nicorandil: advantages over other potassium channel openers.
    Jayawant AM; Lawton JS; Hsia PW; Damiano RJ
    Circulation; 1997 Nov; 96(9 Suppl):II-240-6. PubMed ID: 9386105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A symposium: A new treatment for angina pectoris and heart failure. October 17, 1987, San Francisco. Proceedings.
    Am J Cardiol; 1989 Jun; 63(21):1J-85J. PubMed ID: 2525318
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Satoh K
    Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NICORANDIL EFFICACY IN THE TREATMENT OF ISCHEMIC HEART DISEASE (REVIEW).
    Gvishiani M; Gabunia L; Makharadze T; Gongadze N
    Georgian Med News; 2018; (280-281):152-155. PubMed ID: 30204115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Potassium channel openers. A new possible therapeutic principle in several diseases].
    Drottning P; Christensen H; Storstein L
    Tidsskr Nor Laegeforen; 1994 Feb; 114(4):450-3. PubMed ID: 8009483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease.
    Sasaki J; Saeki Y; Kawasaki K; Umeno M; Ikeda K; Handa K; Arakawa K
    Cardiovasc Drugs Ther; 1992 Oct; 6(5):471-4. PubMed ID: 1450091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An ATP-sensitive potassium (KATP) channel opener, nicorandil, lowers the threshold for ischemic preconditioning in barbital-anesthetized dogs.
    Mizumura T; Saito S; Ozawa Y; Kanmatsuse K; Gross GJ
    Heart Vessels; 1997; Suppl 12():175-7. PubMed ID: 9476575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations in macrophage free radical and tumor necrosis factor production by a potassium channel activator.
    Pogrebniak HW; Matthews W; Pass HI
    J Surg Res; 1992 Apr; 52(4):395-400. PubMed ID: 1534387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
    Longman SD; Clapham JC; Wilson C; Hamilton TC
    J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.